IDYA News
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and DevelopmentPR NewswireSOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 SOUTH SAN FRANCISCO, Calif., Sept. 28...
PR Newswire
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and DevelopmentPR NewswireSOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 SOUTH SAN FRANCISCO, Calif., Sept. 28...
PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireSOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /PRNewswire/ -- IDEAYA...
PR Newswire
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational...
PR Newswire
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 SOUTH...
PR Newswire
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on...
PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 /PRNewswire/ -- IDEAYA...
PR Newswire
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 19, 2026 IDEAYA...
PR Newswire
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 4, 2026 Registrational OptimUM-02 trial of the darovasertib...
PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., July 31, 2026 SOUTH SAN FRANCISCO, Calif., July 31, 2026 /PRNewswire/ -- IDEAYA...
PR Newswire
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor...
PR Newswire